Figure 10.

Treatment of corneal alkali burn in WT mice with a TRPV1 antagonist of SB366791. A: The corneas of WT mice treated with or without SB366791 at 5, 10, or 20 days, respectively. At each time point, corneal transparency restoration is markedly improved in the mice treated with the TRPV1 antagonist SB366791. At day 20 the iris is seen through the transparent cornea in an antagonist-treated mouse, although not in an untreated mouse. B: Evaluation of the alteration of the diameter of the eyeball during wound healing after alkali burn shows that untreated globes have a smaller diameter at 20 days than antagonist-treated globes. C: Histology of burned corneas stained with H&E and IHC findings at days 5 and 10. The stromal organization is poorer in untreated mice than in antagonist-treated mice as judged by H&E histology. The antagonist-treated mice have lower levels of infiltration of MPO-labeled neutrophils at day 5 and F4/80-positive macrophages at day 10 as well as less marked α-SMA and active TGFβ1 staining at both time points. Scale bar = 100 μm.